checkAd

     161  0 Kommentare Sensus Healthcare Announces New $3 Million Share Repurchase Program

    BOCA RATON, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces that its Board of Directors has authorized a new share repurchase program under which the Company may repurchase up to $3.0 million of its common stock.

    “Given our optimism about the future of Sensus, we believe repurchasing our own stock is one of the best uses of our cash,” said Joe Sardano, chairman and chief executive officer of Sensus Healthcare.  “We will continue to deploy cash judiciously to fund initiatives that will provide the highest returns, and are fortunate to have a balance sheet that allows for multiple avenues for capital allocation.”

    The timing and amount of any share repurchases under this program will be determined by Sensus Healthcare’s management at its discretion based upon its ongoing assessments of the capital needs of the business, the market price of Sensus’ common stock and general market conditions. Share repurchases under this program may be made through a variety of methods including open-market purchases, block trades, exchange transactions or any combination thereof. The program does not obligate Sensus to acquire any particular amount of its common stock, and the share repurchase program may be suspended or discontinued at any time at the company’s discretion.

    About Sensus Healthcare

    Sensus Healthcare, Inc. is a medical device company specializing in highly effective, non-invasive, minimally invasive and cost-effective treatments for both oncological and non-oncological conditions. Sensus offers its proprietary low-energy X-ray technology known as superficial radiation therapy (SRT), which is the culmination of more than a decade of research and development, to treat non-melanoma skin cancers and keloids with its SRT-100, SRT-100+ and SRT-100 Vision systems. With its portfolio of innovative medical device products, including aesthetic lasers and its needleless TransDermal Infusion System, Sensus provides revolutionary treatment options to enhance the quality of life of patients around the world.

    Seite 1 von 3



    globenewswire
    0 Follower
    Autor folgen

    Verfasst von globenewswire
    Sensus Healthcare Announces New $3 Million Share Repurchase Program BOCA RATON, Fla., Aug. 08, 2023 (GLOBE NEWSWIRE) - Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and …